These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 25104068

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
    Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, Lu Y, Nelson S, McKnight TR.
    Int J Radiat Oncol Biol Phys; 2005 May 01; 62(1):20-31. PubMed ID: 15850898
    [Abstract] [Full Text] [Related]

  • 4. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
    Muruganandham M, Clerkin PP, Smith BJ, Anderson CM, Morris A, Capizzano AA, Magnotta V, McGuire SM, Smith MC, Bayouth JE, Buatti JM.
    Int J Radiat Oncol Biol Phys; 2014 Sep 01; 90(1):181-9. PubMed ID: 24986746
    [Abstract] [Full Text] [Related]

  • 5. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.
    Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, Nelson SJ, Pirzkall A.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):381-9. PubMed ID: 17513061
    [Abstract] [Full Text] [Related]

  • 6. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
    Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):126-37. PubMed ID: 15093908
    [Abstract] [Full Text] [Related]

  • 7. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU.
    Rofo; 2006 Jun 01; 178(6):627-33. PubMed ID: 16703499
    [Abstract] [Full Text] [Related]

  • 8. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.
    Parra NA, Maudsley AA, Gupta RK, Ishkanian F, Huang K, Walker GR, Padgett K, Roy B, Panoff J, Markoe A, Stoyanova R.
    Int J Radiat Oncol Biol Phys; 2014 Oct 01; 90(2):376-84. PubMed ID: 25066215
    [Abstract] [Full Text] [Related]

  • 9. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
    Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL.
    J Neurooncol; 2005 Jan 01; 71(2):173-80. PubMed ID: 15690135
    [Abstract] [Full Text] [Related]

  • 10. Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of Glioblastoma Multiforme.
    Lopez CJ, Nagornaya N, Parra NA, Kwon D, Ishkanian F, Markoe AM, Maudsley A, Stoyanova R.
    Int J Radiat Oncol Biol Phys; 2017 Mar 01; 97(3):586-595. PubMed ID: 28011044
    [Abstract] [Full Text] [Related]

  • 11. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.
    Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ.
    J Magn Reson Imaging; 2004 May 01; 19(5):546-54. PubMed ID: 15112303
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
    Elias AE, Carlos RC, Smith EA, Frechtling D, George B, Maly P, Sundgren PC.
    Acad Radiol; 2011 Sep 01; 18(9):1101-8. PubMed ID: 21820634
    [Abstract] [Full Text] [Related]

  • 14. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Nelson SJ, Kadambi AK, Park I, Li Y, Crane J, Olson M, Molinaro A, Roy R, Butowski N, Cha S, Chang S.
    Neuro Oncol; 2017 Mar 01; 19(3):430-439. PubMed ID: 27576874
    [Abstract] [Full Text] [Related]

  • 15. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma.
    Chan AA, Lau A, Pirzkall A, Chang SM, Verhey LJ, Larson D, McDermott MW, Dillon WP, Nelson SJ.
    J Neurosurg; 2004 Sep 01; 101(3):467-75. PubMed ID: 15352605
    [Abstract] [Full Text] [Related]

  • 16. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions.
    Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC.
    AJR Am J Roentgenol; 2009 Feb 01; 192(2):W45-52. PubMed ID: 19155380
    [Abstract] [Full Text] [Related]

  • 17. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
    Zeng QS, Li CF, Liu H, Zhen JH, Feng DC.
    Int J Radiat Oncol Biol Phys; 2007 May 01; 68(1):151-8. PubMed ID: 17289287
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
    Nelson SJ, Li Y, Lupo JM, Olson M, Crane JC, Molinaro A, Roy R, Clarke J, Butowski N, Prados M, Cha S, Chang SM.
    J Neurooncol; 2016 Oct 01; 130(1):171-179. PubMed ID: 27535746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.